Cys-McMMAF

• UNSPSC Description:

  Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models)[1].

• Target Antigen:

  Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cys-mcmmaf.html

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  OC([C@H](CC1=CC=CC=C1)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCCN3C(C(CC3=O)SC[C@H](N)C(O)=O)=O)=O)=O)=O)=O)OC)=O)=O

• Molecular Weight:

  1046.32

• References & Citations:

  [1]Leal M, et al. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice. Bioconjug Chem. 2015 Nov 18;26(11):2223-32.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  1160590-05-5